Real-world data demonstrated 92% vaccine effectiveness against hospitalisations due to the Delta variant
New data from
Real world data from PHE, published as a pre-print, demonstrated two doses of COVID-19 Vaccine AstraZeneca are 92% effective against hospitalisation due to the Delta variant and showed no deaths among those vaccinated. The vaccine also showed a high level of effectiveness against the Alpha variant (B.1.1.7; formerly the 'Kent' variant) with an 86% reduction of hospitalisations and no deaths reported.
The data suggest that vaccine effectiveness against milder symptomatic disease, although significant, was lower. Vaccine effectiveness against symptomatic disease was 74% against the Alpha variant and 64% against the Delta variant.
The higher efficacy against severe disease and hospitalisation is supported by recent data showing strong T-cell response to COVID-19 Vaccine AstraZeneca, which should correlate with high and durable protection.1
The analysis included 14,019 cases of the Delta variant - 166 of whom were hospitalised - between 12 April and 4 June, looking at emergency hospital admissions in
This real world evidenceagainst the Delta variant is based on limited follow up after the second dose which could impact the effectiveness estimate.
The Delta variant is a key contributor to the current wave of infection in the Indian subcontinent and beyond. It has recently replaced the Alpha variant as the dominant strain in
COVID-19 Vaccine AstraZeneca, formerly AZD1222
COVID-19 Vaccine AstraZeneca was co-invented by the
The vaccine has been granted a conditional marketing authorisation or emergency use in more than 80 countries across six continents. More than 500 million doses of COVID-19 Vaccine AstraZeneca have been supplied to 165 countries worldwide, including more than 100 countries through the COVAX Facility.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
ReferenceParry HM, et al. (2021) Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1. Preprints with
.
(C) 2021 M2 COMMUNICATIONS, source